The NIH awarded Boston University’s National Emerging Infectious Diseases Laboratories a five-year, $57.5 million grant to support operations and research on priority pathogens. The funding is intended to sustain high-containment laboratory capability for emerging infectious disease investigations. For biotech stakeholders, expanded biocontainment capacity can accelerate preclinical work in therapeutics and diagnostics by improving access to properly controlled pathogen research settings. The grant’s duration and scale also signal continued federal investment in preparedness infrastructure, which tends to translate into longer planning horizons for platform and product development programs tied to high-consequence pathogens.